Williams R J, McCarthy A D, Sutherland C D
Department of Biochemistry, Glaxo Group Research Ltd., Greenford, Middlesex, U.K.
Biochim Biophys Acta. 1989 Jun 8;1003(2):213-6. doi: 10.1016/0005-2760(89)90259-2.
Activity of the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) in isolated rat enterocytes was reduced by approx. 75% following a single oral dose of Sandoz compound 58-035 (30 mg.kg-1). Despite this, the formation of [14C]cholesteryl esters from [1-14C]oleic acid remained unaffected in ACAT-inhibited cell preparations. The increase in serum cholesterol concentrations observed after overnight cholesterol/cholic acid (1%/0.5%) feeding to rats was abolished by pre-treatment with Sandoz compound 58-035 (30 mg.kg-1). These results can be reconciled with a previously proposed model for the transmembrane movement of cholesterol which implicates ACAT-independent esterification and hydrolysis as a transport mechanism for the movement of cholesterol across the enterocyte apical membrane.
单次口服桑多兹化合物58 - 035(30毫克/千克)后,分离出的大鼠肠上皮细胞中酰基辅酶A:胆固醇酰基转移酶(ACAT)的活性降低了约75%。尽管如此,在ACAT受抑制的细胞制剂中,由[1 - 14C]油酸形成[14C]胆固醇酯的过程仍未受影响。给大鼠喂食过夜的胆固醇/胆酸(1%/0.5%)后观察到的血清胆固醇浓度升高,在预先用桑多兹化合物58 - 035(30毫克/千克)处理后被消除。这些结果与先前提出的胆固醇跨膜转运模型相符,该模型认为不依赖ACAT的酯化和水解是胆固醇跨肠上皮细胞顶端膜转运的一种机制。